Sustained Release Intravitreal Corticosteroid Injections

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43EY017227-01
Agency Tracking Number: EY017227
Amount: $99,368.00
Phase: Phase I
Program: SBIR
Awards Year: 2006
Solicitation Year: 2006
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Small Business Information
AURITEC PHARMACEUTICALS, INC., 2275 E FOOTHILL BLVD, PASADENA, CA, 91107
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 THOMAS SMITH
 (626) 376-4070
 tsmith@auritecpharma.com
Business Contact
 THOMAS SMITH
Phone: (626) 376-4070
Email: TSMITH@AURITECPHARMA.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The long term goal of this research is to reduce or eliminate blindness due to diseases of the back of the eye by developing sustained release intravitreal injectable formulations for anti-inflammatory drugs. In previous work, supported in part through SBIR Phase 1 and 2 funding, the Principal Investigator has developed the Vitrasert(r) sustained release implant approved by the FDA for the treatment of CMV retinitis in 1995, and the Retisert(tm) sustained release implant currently under NDA review by the FDA. The specific aims of this application are to: 1, formulate sustained release suspensions of fluocinolone acetonide; 2, test the in vitro release characteristics of these formulations into buffer; and 3, test the in vivo pharmacokinetics and the safety of the formulations after intravitreal injection in the rabbit. The team of investigators is expert in polymer chemistry, pharmacokinetics and drug development. We have experience in all aspects of the drug development process, from concept to approval and marketing. The successful completion of these specific aims will constitute a readily identifiable milestone which will permit us to continue with Phase 2 of this application where we will test the efficacy of the devices in animal models of posterior uveitis and complete the requisite laboratory work to apply for an Investigational New Drug Exemption from the FDA.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government